TP53 and neoplasm: Despite a much lower rate of concordant TP53 mutation, there was also a significant association between STAG2 mutation and decreased CDKN1A transcript expression in the tumor cohort (log2 FPKM 4.08 vs 5.18, p = 0.039) (Figure S9C) and a trend towards increased TP53 expression (log2 FPKM 5.51 vs. 5.38, p = 0.19).